author-photo

Tomoharu Sugie

Kansai Medical University
Kyoto University

114

Papers

1180

Citations

Citation Trend

Filter By

Papers (66) Sort By

Journal Conference Others

Possible Case of IgG4-related Mastitis : A Case Report and Review of the Literature

2021
Show All
- Source
- Cite
- Save
Citations (0)
Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.

2021 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (1)
Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.

2021 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS13-31: Prospective observational study to explore the effectiveness of eribulin as first- or second- line chemotherapy in patients with HER2-negative hormone-resistant advanced or metastatic breast cancer (KBCRN A001: E-SPEC study)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Multi-institutional prospective observational study of the effectiveness of eribulin in first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: The KBCRN A001: E-SPEC Study

2021
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.

2021 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (6)
Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.

2020 Breast Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity.

2020 Cancer Immunology, Immunotherapy
Show All
- Source
- Cite
- Save
Citations (1)
Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)